Following the webinar I sent the following email to Investor...

Following the webinar I sent the following email to Investor Relations, as suggested for anyone with unanswered questions from the webinar. Almost a month now and received no reply. Concerned at lack of any commercial progress with HTert or exosomes, and bit confused by apparent competition between SubB2m and Exosomes in developing technology and products that target the same cancer screening markets. Worry that not another experience or focus at Board or management level in commercialising technolgy - seem to be more research focussed. Hope I'm wrong.

I lodged a few questions that weren’t addressed in the Webinar on Tuesday 10/5/22, and as suggested am contacting Investor Relations to see if they can be answered. My concerns with Inoviq are that it is not sufficiently commercially focussed and the webinar only reinforced that feeling as I found it to be slippery with figures and the end of session questions came across as ‘dorothy dixers’ framed by the PR department. What wasn’t clarified for me was:

- When asked a ‘Dorothy Dixer’ about the cash position, the Finance Manager said they had 13 Quarters of cash based on the March quarter cash outflow and cash balance. However what he neglected to outline was what the cash outflow will increase to in the future quarters with the recent engagements of Research Dx, MP Biomedicals and the employment of additional executives. Perhaps that 13 quarters declines significantly when looking forward rather than backward? It seemed like a political answer rather than an honest one.

- Some worldwide market size figures were quoted for Exosomes but the presentation indicated IIQ would be seeking collaborations for the use of its technology rather than regular sales. Given that Exonet has been on the market for 12 months now, and earnt zero sales, what level of sales (not collaborations) is the company targeting in the near future?

- Some worldwide market size figures were quoted for testing for ovarian, breast, pancreatic and prostate cancers. There were also timeline graphs for the progression of SubB2m toward use for Ovarian and Breast cancer testing. However IIQ is targeting the LDT market initially. There was no breakdown of the LDT market for ovarian and breast cancer testing as opposed to the total market, and no timeline indicated for progressing these through large scale clinical trials to support IVD approval so that it can then target a percentage of the worldwide market that was quoted. In summary I have no idea of what size market IIQ is targeting toward the end of 2023 and into 2024, nor how long until it might be able to target those quoted world markets.

- Why is SubB2m being released for monitoring and not diagnosis? Is it because the LDT market only deals with monitoring and not diagnosis? Once again what does this do to IIQ’s potential share or timing of access to the worldwide market figures that were quoted?

- Not much coverage or hope was given to Htert going forward, just the excuse that Covid has restricted sales in the recent past. Once again this felt more like a political answer rather than an honest one. What is the outlook (if any) for HTert?

While pleased that the company held the webinar, I was left a little dis-satisfied. It felt heavily scripted with big input from Investor Relations. It made the employees who presented, come across as mercenaries rather than fellow shareholders. It doesn’t feel right to be asking Investor Relations to fill in some of the gaps in the presentation, but perhaps you can consult with management and provide whatever information you can without compromising market sensitivity.